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Abstract
Background
The link of low estimated glomerular filtration rate (eGFR) and high proteinuria to cardiovas-
cular disease (CVD) mortality is well known. However, its link to mortality due to other
causes is less clear.
Methods
We studied 367,932 adults (20–93 years old) in the Korean Heart Study (baseline between
1996–2004 and follow-up until 2011) and assessed the associations of creatinine-based
eGFR and dipstick proteinuria with mortality due to CVD (1,608 cases), cancer (4,035
cases), and other (non-CVD/non-cancer) causes (3,152 cases) after adjusting for potential
confounders.
Results
Although cancer was overall the most common cause of mortality, in participants with chronic
kidney disease (CKD), non-CVD/non-cancer mortality accounted for approximately half of
cause of death (47.0%for eGFR <60ml/min/1.73m2 and 54.3% for proteinuria ≥1+). Lower
eGFR (<60 vs. ≥60ml/min/1.73m2) was significantly associated with mortality due to CVD
(adjusted hazard ratio 1.49 [95%CI, 1.24–1.78]) and non-CVD/non-cancer causes (1.78 [1.54–
2.05]). The risk of cancer mortality only reached significance at eGFR <45ml/min/1.73m2 when
eGFR 45–59ml/min/1.73m2 was set as a reference (1.62 [1.10–2.39]). High proteinuria (dip-
stick ≥1+ vs. negative/trace) was consistently associated with mortality due to CVD (1.93
[1.66–2.25]), cancer (1.49 [1.32–1.68]), and other causes (2.19 [1.96–2.45]). Examining finer
mortality causes, low eGFR and high proteinuria were commonly associated with mortality due
to coronary heart disease, any infectious disease, diabetes, and renal failure. In addition, pro-
teinuria was also related to death from stroke, cancers of stomach, liver, pancreas, and lung,
myeloma, pneumonia, and viral hepatitis.
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Conclusion
Low eGFR was associated with CVD and non-CVD/non-cancer mortality, whereas higher
proteinuria was consistently related to mortality due to CVD, cancer, and other causes.
These findings suggest the need for multidisciplinary prevention and management strate-
gies in individuals with CKD, particularly when proteinuria is present.
Introduction
Chronic kidney disease (CKD), defined as reduced kidney function and/or kidney damage, is a
worldwide public health problem [1–3]. The prevalence of CKD is 10–15% in Asia, Europe,
and the USA [1, 3–6]. Cardiovascular disease (CVD) is an important complication of CKD
since up to half of this population dies from CVD [7–14]. Indeed, numerous studies have
reported the significant associations of lower estimated glomerular filtration rate (eGFR) and
higher proteinuria with CVD mortality [10, 13–15].
Several studies also report the associations of these CKD measures with all-cause mortality
[7–11]. This may merely reflect the link between CKD and CVDmortality, given that CVD is a
leading cause of death in many places of the world [16]. On the other hand, reduced kidney
function may relate to mortality due to cancer, the other worldwide leading cause of death [17–
19]. However, to our knowledge, the only study to simultaneously investigate both key CKD
measures, eGFR and proteinuria [20], did not find a significant association between CKD and
cancer mortality [12]. Thus, further studies are needed, particularly to investigate the relation-
ship between proteinuria and cancer mortality.
Although CVD and cancer are clearly important as causes of death, other causes account for
approximately 30–35% of deaths in developed countries [16], and thus also warrant attention.
A few studies have investigated the association of CKD with deaths due to non-CVD/non-can-
cer causes [17, 19, 21, 22]. Infection-related mortality has been most extensively examined in
this context but has demonstrated conflicting results across studies [17, 19, 21, 23]. Moreover,
of these, only one study explored proteinuria [21], and mortality causes other than infectious
disease have not been systematically investigated [17, 19, 21–23].
Since prevention and management can be substantially different across diseases, simulta-
neously quantifying the respective associations of CKD measures with cause-specific mortality
in a single cohort is important from both clinical and public health perspectives. Therefore, we
assessed whether creatinine-based eGFR and dipstick proteinuria were associated with mortal-
ity due to CVD, cancer, and other causes in more than 350,000 Korean adults. The large sample
size allowed us to also investigate finer representative causes of death.
Materials and Methods
Study population
The Korean Heart Study (KHS) is a retrospective cohort study based on data from private
health examinations conducted at 18 centers in South Korea from 1996–2004 [24]. Of these
centers, 14 centers opted in to the present cause-specific mortality study. The record linkage
for mortality was based on an official personal identification number and identified 521,585
study members aged 20 years or older with a health assessment at baseline. We excluded partic-
ipants with missing information on serum creatinine (n = 37,196) and dipstick urinary test
(n = 116,457), leaving the final study population of 367,932 participants. The Institutional
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Review Board of Human Research of Yonsei University and all the individual centers partici-
pating in the KHS approved the investigation.
Data collection
Demographic information, smoking status (never, past, or current), and medical history of
comorbidities including CVD and cancer were assessed with questionnaires. Weight and
height measurements were recorded while participants were wearing light clothing. Trained
staff measured blood pressure. Blood samples were obtained after 12h of fasting. Total choles-
terol, triglyceride, high-density lipoprotein cholesterol, fasting glucose, and liver enzymes
(aspartate aminotransferase and alanine aminotransferase) were measured at each center using
auto analyzers. The seropositivity to hepatitis B and C viruses was measured with radioimmu-
noassay or reverse passive haemagglutination in participating laboratories. Each center had
internal and external quality control procedures as required by the Korean Association of Lab-
oratory Quality Control [24]. Diabetes was defined as fasting glucose ≥126 mg/dl, use of glu-
cose-lowering medication, or history of diabetes.
Assessment of eGFR and dipstick proteinuria
Serum creatinine was measured using the kinetic rate Jaffe method, and GFR was estimated by
the CKD-EPI equation, after reducing the creatinine level by 5%, the calibration factor to adjust
a nonstandardized assay to creatinine standardized to isotope dilution mass spectrometry at
the Cleveland Clinic Laboratory [25, 26]. Proteinuria was assessed by dipstick test using an
automated urine analyzer, and was recorded as negative, trace, 1+, 2+, 3+, and 4+ in all centers
except one systematically recording negative and trace together as low proteinuria.
Follow-up for mortality
Death certificate linkage data until 31 December 2011 were provided by the Korean National
Statistical Office. Based on the ICD code for primary cause of death, mortality was categorized
into CVD (Disease of circulatory system: ICD-10 codes I00-I99 and sudden death: R96), cancer
(C00-C97), and other (non-CVD/non-cancer) causes (all other ICD-10 codes) (S1 Table).
Statistical analysis
Baseline characteristics are presented as mean and standard deviation (SD) for continuous var-
iables and percentage for categorical variables across categories of eGFR (≥90, 60–89, 45–59,
and<45 ml/min/1.73m2) and dipstick proteinuria (none/trace, 1+, 2+, and ≥3+). We com-
bined all participants with eGFR<45 ml/min/1.73m2 since few participants (n = 168 [0.05%])
had eGFR<30 ml/min/1.73m2. The age-standardized cause-specific mortality was calculated
across these categories using the Korean Population and Housing Census data in 2010 as a
standard population [27].
Subsequently, we quantified the associations of eGFR and proteinuria with cause-specific
mortality using Cox proportional hazards models. Since a J-shaped association has been seen
for eGFR and morality risk [20, 28] and the lowest risk category varies across studies, for this
analysis [8, 10, 14], we subdivided ≥90 and 60–89 ml/min/1.73m2 into ≥105, 90–104, 75–89,
and 60–74. eGFR 75–89 ml/min/1.73m2 was the most prevalent category in those aged ≥50
years, a group with higher mortality than younger individuals, and thus we selected this cate-
gory as the reference, as done previously [12, 29]. For dipstick proteinuria, we selected none/
trace as the reference since one center recorded negative and trace proteinuria as a single cate-
gory. However, using data from the other 13 centers, we also tested dipstick negative as a
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reference. Three models were constructed to evaluate the impact of potential confounders.
Model 1 was unadjusted, and Model 2 incorporated age and gender. Model 3 further adjusted
for smoking, body mass index, total cholesterol, systolic blood pressure, antihypertensive medi-
cations, diabetes, and history of CVD and cancer, and each of the CKD measures, as appropri-
ate (proteinuria was incorporated in the analyses for eGFR and vice versa). We implemented
multiple imputation [30] to impute smoking status (missing in 200,887 participants), diabetes
(20 participants), systolic blood pressure (362 participants), and total cholesterol (17 partici-
pants) using other predictors in Model 3, mortality outcomes, and follow-up time. We repeated
our analysis in several subgroups by age (< and ≥60 years), gender, and history of CVD and
cancer (yes vs. no) at baseline.
For finer causes of mortality, to obtain reliable estimates, we primarily analyzed causes with
≥50 deaths and modeled the kidney measures as dichotomous variables (eGFR< vs. ≥60 ml/
min/1.73m2 and dipstick proteinuria ≥1+ vs. none/trace). All analyses were performed using
STATA version 12. All statistical tests were two-sided and statistical significance was deter-
mined as p<0.05.
Results
The mean age of the study participants was 41.7 (SD, 10.9) years and 41.5% were women. The
average eGFR was 94.2 (SD, 14.4) ml/min/1.73m2. Of the study participants, 1.0% (n = 3,642)
had eGFR below 60 ml/min/1.73m2 and 3.7% (n = 13,499) had dipstick proteinuria ≥1+. Those
with lower eGFR (<60 ml/min/1.73m2) or higher dipstick proteinuria (≥1+) were more likely
to be older, male, and have diabetes, hypertension, and hypercholesterolemia compared to
those with higher eGFR (≥60 ml/min/1.73m2) and lower proteinuria (negative/trace), respec-
tively (Table 1).
During the median follow-up of 9.8 years, 8,795 participants died (1,608 from CVD, 4,035
from cancer, and 3,152 from other [non-CVD/non-cancer] causes). Age-standardized mortal-
ity rates were largely similar in eGFR ≥90 and 60–89 ml/min/1.73m2 categories but sharply
increased in the eGFR<45 ml/min/1.73m2 category (Figs 1 and 2). Cancer was the most com-
mon cause of death only among those with eGFR 60–89 ml/min/1.73m2 (42.3%), but for other
eGFR categories including those of eGFR<60 ml/min/1.73m2, non-CVD/non-cancer causes
accounted for 40%-50% of cause of death (47.0% in those with eGFR<60 ml/min/1.73m2).
Similarly, non-CVD/non-cancer mortality accounted for a great part of cause of death among
those with positive proteinuria (≥1+) (54.3%), whereas cancer was the most common cause of
death among those with none/trace dipstick proteinuria (41.2%). CVD was more common
than cancer as a cause of death only among those with dipstick proteinuria ≥3+ (25.6% vs.
20.4%).
In crude models, there was a clear dose-response relationship between eGFR and mortality
due to CVD, cancer, and non-CVD/non-cancer (Table 2). Once adjusted for demographic fac-
tor (Model 2), the associations were somewhat attenuated for all types of mortality and demon-
strated U-shape. After further adjusting for potential confounders (Model 3), with eGFR 75–89
ml/min/1.73m2 as a reference, eGFR categories below 60 ml/min/1.73m2 were significantly
associated with higher mortality due to CVD and non-CVD/non-cancer causes but not cancer
mortality. For cancer mortality, in Model 3 we observed the lowest risk at eGFR 45–59 ml/
min/1.73m2, when we set this category as a reference eGFR<45 ml/min/1.73m2 demonstrated
a significant association (1.62 [1.10–2.39]). Significantly positive associations with higher
eGFR categories compared to eGFR 75–89 ml/min/1.73m2 in Model 3 were observed for can-
cer and non-CVD/non-cancer mortality. We observed generally similar patterns in subgroups
by gender and age (< vs. ≥60 years) (S2 and S3 Tables). Also, the results were similar among
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those without history of CVD or cancer at baseline (S4 Table). For dichotomous eGFR, eGFR
<60 (vs. ≥60) ml/min/1.73m2 was significantly associated with mortality due to CVD (1.49
[1.24–1.78]) and non-CVD/non-cancer causes (1.78 [1.54–2.05]) but not mortality due to can-
cer (0.86 [0.73–1.01]) in Model 3.
Table 1. Baseline characteristics by eGFR and dipstick in Korean Heart Study, N = 367,932.
eGFR, ml/min/1.73m2 Dipstick proteinuria
≥90 60–89 45–59 <45 None/trace 1+ 2+ ≥3+
N = 227,370 N = 136,920 N = 3,136 N = 506 N = 354,433 N = 10,090 N = 2,545 N = 864
Age, years 38.2(9.3) 46.9(10.8) 61.2(9.9) 58.1(13.4) 41.6 (10.9) 42.7 (11.8) 44.2 (12.5) 47.1 (12.8)
Female 44.51 36.33 53.09 46.05 41.80 34.07 36.27 34.95
Smoking status
Ex-smoker 5.34 8.81 14.51 12.85 14.76 14.54 16.54 22.15
Current smoker 14.45 17.00 12.34 15.22 33.39 43.72 39.72 36.97
Cardiovascular disease 0.35 0.79 3.22 3.56 0.51 1.14 1.57 1.50
Cancer 0.19 0.26 0.48 0.59 0.21 0.37 0.24 0.35
Diabetes 3.6 5.72 12.21 21.34 4.04 14.13 20.31 26.62
Anti-diabetes medication use 0.57 0.96 3.19 7.51 0.66 2.59 3.50 8.33
Fasting glucose, mg/dl 90.2(20.1) 94.3(21.8) 101.5(31.3) 103.6(35.5) 91.3 (19.6) 103.5 (38.5) 110.3 (46.3) 117.3 (54.4)
Anti-hypertension medication use 1.56 3.96 15.05 26.28 2.42 6.40 9.19 14.81
Hypertension 18.85 29.08 54.37 69.57 22.44 35.62 46.40 57.64
Systolic blood pressure, mmHg 116.9(16.0) 122.1(18.1) 134.4(22.2) 142.0(25.6) 118.8 (16.9) 124.2 (20.4) 129.0 (23.2) 137.2 (27.0)
Diastolic blood pressure, mmHg 73.9(11.3) 76.5(12.0) 78.4(13.4) 82.4(15.5) 74.8 (11.5) 78.3 (13.3) 80.7 (14.6) 82.0 (15.2)
Hypercholesterolemia 5.32 10.27 20.5 23.32 7.08 11.87 15.60 27.89
Total cholesterol, mmol/l 4.7(0.9) 5.0(0.9) 5.4(1.0) 5.3(1.4) 4.8 (0.8) 5.0 (1.0) 5.2 (1.1) 5.6 (1.3)
HDL-cholesterol, mmol/l 1.3(0.3) 1.3(0.3) 1.3(0.3) 1.2(0.3) 1.3 (0.3) 1.3 (0.3) 1.3 (0.3) 1.2 (0.3)
Triglyceride, mmol/l 1.5(1.1) 1.7(1.1) 1.9(1.2) 2.2(1.5) 1.6 (1.1) 1.8 (1.4) 2.0 (1.7) 2.3 (1.9)
LDL-cholesterol, mmol/l 2.8(0.8) 3.0(0.8) 3.3(1.0) 3.2(1.2) 2.9 (0.8) 2.9 (0.9) 3.1 (1.0) 3.4 (1.2)
Height, cm 165.3(8.3) 164.9(8.6) 160.1(8.6) 160.9(9.1) 165.1 (8.5) 165.8 (8.1) 164.9 (8.3) 164.4 (8.4)
Weight, kg 63.0(11.5) 65.3(10.8) 63.6(10.4) 62.1(10.5) 63.8 (11.2) 65.4 (12.1) 65.8 (12.9) 65.4 (12.4)
Body mass index, kg/m2 23.0(3.2) 23.9(3.0) 24.7(3.1) 23.9(3.3) 23.3 (3.1) 23.7 (3.5) 24.1 (3.8) 24.1 (3.7)
Obesity 2.12 2.65 4.91 4.55 2.26 4.05 5.89 6.25
Serum creatinine, mg/dl 0.8(0.1) 1.0(0.1) 1.2(0.2) 2.5(2.2) 0.9 (0.2) 1.0 (0.3) 1.0 (0.5) 1.3 (1.4)
eGFR, ml/min/1.73m2 103.2(8.9) 80.3(7.1) 55.7(3.5) 32.6(11.5) 94.4 (14.2) 91.3 (16.5) 86.5 (20.6) 77.4 (26.5)
doi:10.1371/journal.pone.0153429.t001
Fig 1. Age-standardized mortality rate (per 1000 person-years) by eGFR.
doi:10.1371/journal.pone.0153429.g001
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High proteinuria was consistently associated with CVD, cancer, and non-CVD/non-cancer
mortality, with a robust dose-response relationship, even after accounting for potential con-
founders (Table 3). For all mortality outcomes, risk was significantly increased even in the 1+
proteinuria group. When we used data from the 13 centers (N = 178,603 and 6,448 deaths)
Fig 2. Age-standardized mortality rate (per 1000 person-years) by dipstick proteinuria.
doi:10.1371/journal.pone.0153429.g002
Table 2. Hazard ratios (95%CI) for cause-specific mortality by eGFR in Korean Heart Study.
eGFR, ml/min/1.73m2
≥105 90–104 75–89 60–74 45–59 <45
N = 87,468 N = 139,902 N = 105,839 N = 31,081 N = 3,136 N = 506
CVD mortality
Cases 103 447 570 335 118 35
Model 1 0.22 (0.18–0.27) 0.59 (0.53–0.67) 1.0 1.98 (1.73–2.27) 7.17 (5.88–8.74) 14.57 (10.35–20.49)
Model 2 1.19 (0.95–1.49) 1.05 (0.93–1.20) 1.0 1.03 (0.90–1.18) 1.62 (1.32–2.00) 3.59 (2.53–5.07)
Model 3 1.17 (0.93–1.46) 1.03 (0.91–1.17) 1.0 0.99 (0.86–1.13) 1.34 (1.90–1.66) 2.09 (1.45–3.01)
Cancer mortality
Cases 339 1,287 1,507 741 128 33
Model 1 0.27 (0.24–0.30) 0.65 (0.60–0.70) 1.0 1.66 (1.52–1.81) 2.94 (2.45–3.52) 5.19 (3.67–7.32)
Model 2 1.28 (1.12–1.45) 1.09 (1.01–1.18) 1.0 0.91 (0.83–1.00) 0.75 (0.63–0.91) 1.46 (1.03–2.07)
Model 3 1.16 (1.02–1.32) 1.04 (0.97–1.13) 1.0 0.95 (0.87–1.04) 0.78 (0.65–0.94) 1.26 (0.88–1.80)
Non-CVD/non-cancer mortality
Cases 396 1,019 992 512 153 80
Model 1 0.47 (0.42–0.53) 0.78 (0.71–0.85) 1.0 1.74 (1.56–1.93) 5.32 (4.49–6.31) 19.09 (15.20–23.97)
Model 2 2.01 (1.77–2.29) 1.26 (1.15–1.38) 1.0 0.99 (0.89–1.10) 1.48 (1.24–1.76) 5.86 (4.64–7.39)
Model 3 1.73 (1.51–1.91) 1.19 (1.09–1.30) 1.0 1.02 (0.92–1.14) 1.41 (1.18–1.68) 3.35 (2.61–4.31)
All-cause mortality
Cases 838 2,753 3,069 1,588 399 148
Model 1 0.32 (0.30–0.35) 0.68 (0.64–0.71) 1.0 1.74 (1.64–1.85) 4.50 (4.05–4.90) 11.42 (9.67–13.47)
Model 2 1.53 (1.40–1.66) 1.14 (1.08–1.20) 1.0 0.96 (0.90–1.02) 1.16 (1.04–1.29) 3.24 (2.74–3.83)
Model 3 1.37 (1.26–1.49) 1.90 (1.03–1.15) 1.0 0.98 (0.92–1.04) 1.11 (1.00–1.24) 2.20 (1.84–2.63)
Model 1: unadjusted
Model 2: adjusted for age and gender
Model 3: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, cancer, current smoker, systolic blood pressure, anti-hypertensive,
body mass index and dipstick proteinuria
doi:10.1371/journal.pone.0153429.t002
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with separate data on negative vs. trace dipstick proteinuria, the association of trace dipstick pro-
teinuria was significant or borderline significant for mortality due to CVD (1.39 [1.15–1.69]),
cancer (1.13 [0.99–1.29], p = 0.075), and other causes (1.47 [1.28–1.69]) (S5 Table). The associa-
tions were largely consistent between gender and age subgroups (S6 and S7 Tables) and among
those without history of CVD or cancer (S8 Table). For dichotomous proteinuria, proteinuria
(≥1+) was associated with mortality due to CVD (1.93 [1.66–2.25]), cancer (1.49 [1.32–1.68]),
and other causes (2.19 [1.96–2.45]) compared to dipstick negative/trace in Model 3.
Examining finer mortality causes, low eGFR (<60 vs. ≥60 ml/min/1.73m2) and high protein-
uria (≥1+ vs. none/trace) were both associated with increased risk of death from coronary disease,
any infectious diseases, diabetes, and renal failure (Figs 3 and 4). In addition, low eGFR was signif-
icantly associated with increased risk of death from oropharyngeal cancer as well as paradoxically
with decreased risk of death from lung cancer and liver disease (Fig 3). Proteinuria demonstrated
significant associations with broader mortality causes compared to eGFR such as stroke, cancer of
various organs (i.e., stomach, liver, pancreas, lung, urinary tract), myeloma, and liver disease (Fig
4). For liver outcomes, when we further adjusted for alcohol intake, liver enzymes, and seroposi-
tivity to hepatitis B and C viruses, the association remained significant for mortality from liver
cancer and viral hepatitis (1.41 [1.03–1.94] and 4.06 [1.76–9.39], respectively) but not for mortal-
ity from other types of liver disease (1.38 [0.79–2.38]). Largely consistent results were observed
when we excluded deaths in the first three years of follow-up (S1 and S2 Figs).
Table 3. Hazard ratios (95%CI) for cause-specific mortality by dipstick proteinuria in Korean Heart Study.
Dipstick proteinuria
None/trace 1+ 2+ ≥3+
N = 354,433 N = 10,090 N = 2,545 N = 864
CVD mortality
Cases 1,395 135 42 36
Model 1 1.0 3.07 (2.58–3.66) 4.16 (3.06–5.65) 9.76 (7.01–13.59)
Model 2 1.0 2.40 (2.01–2.87) 2.67 (1.97–3.64) 5.33 (3.82–7.42)
Model 3 1.0 1.86 (1.55–2.24) 1.69 (1.23–2.32) 2.43 (1.68–3.51)
Cancer mortality
Cases 3,725 219 59 32
Model 1 1.0 1.85 (1.61–2.12) 2.18 (1.69–2.82) 3.22 (2.28–4.57)
Model 2 1.0 1.49 (1.30–1.70) 1.47 (1.14–1.91) 1.86 (1.31–2.63)
Model 3 1.0 1.45 (1.26–1.66) 1.47 (1.13–1.91) 1.87 (1.30–2.68)
Non-CVD/non-cancer mortality
Cases 2,750 225 103 74
Model 1 1.0 2.56 (2.23–2.93) 5.15 (4.23–6.27) 10.03 (7.96–12.64)
Model 2 1.0 2.13 (1.86–2.44) 3.65 (3.00–4.44) 6.12 (4.85–7.71)
Model 3 1.0 1.77 (1.54–2.03) 2.67 (2.17–3.28) 3.28 (2.52–4.28)
All-cause mortality
Cases 7,870 579 204 142
Model 1 1.0 2.31 (2.13–2.58) 3.57 (3.11–4.10) 6.77 (5.73–7.99)
Model 2 1.0 1.88 (1.72–2.04) 2.43 (2.12–2.79) 3.94 (3.33–4.65)
Model 3 1.0 1.65 (1.51–1.80) 1.97 (1.71–2.28) 2.65 (2.20–3.18)
Model 1: unadjusted
Model 2: adjusted for age and gender
Model 3: adjusted for age, gender, total cholesterol, diabetes, cardiovascular disease, cancer, current smoker, systolic blood pressure, anti-hypertensive,
body mass index and eGFR
doi:10.1371/journal.pone.0153429.t003
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Discussion
In this large Korean cohort study, we found that low eGFR was mainly associated with CVD
and non-CVD/non-cancer mortality in adjusted analyses, whereas high proteinuria was consis-
tently associated with each of CVD, cancer, and non-CVD/non-cancer mortality. Of note, even
trace proteinuria contributed to increased mortality risk. For finer causes of death, both kidney
markers were associated with increased risk of mortality due to coronary disease, infectious dis-
ease, diabetes, and renal failure. In addition, high proteinuria was also significantly associated
with myriad other causes of death (i.e., stroke, cancer of stomach, liver, pancreas, lung, and uri-
nary tract, myeloma, pneumonia, viral hepatitis, and liver disease).
As previously reported [10, 13–15], we confirmed the significant associations of eGFR and
proteinuria with overall CVDmortality, independent of traditional risk factors. High proteinuria
was significantly associated with death from both coronary disease and stroke, whereas low
Fig 3. Adjusted hazard ratios of cause-specific mortality for eGFR<60 ml/min/1.73m2 (vs.≥60).
doi:10.1371/journal.pone.0153429.g003
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eGFR was only significantly associated with coronary disease mortality. Our finding is consistent
with a few previous studies reporting a stronger association of stroke with high proteinuria than
with low eGFR [31, 32]. Although the exact mechanisms for the strong association between pro-
teinuria and stroke independently of blood pressure are uncertain, this may reflect the property
of proteinuria as an indicator of systemic vascular injury and endothelial dysfunction [31].
The association of low eGFR with cancer mortality was weak and not robust in our study
(only significant in unadjusted models or when we shifted the reference to eGFR 45–59 ml/
min/1.73m2). This seems consistent with conflicting results in previous studies [17–19, 22]. A
few studies reported significant associations of reduced kidney function and cancer mortality
[17–19, 22], but, of note, only one study fully adjusted for important confounders like blood
pressure, diabetes, lipids, and proteinuria [22]. One UK study accounted for these confounders
and did not observe significant associations of CKD, defined as reduced eGFR and/or elevated
Fig 4. Adjusted hazard ratios of cause-specific mortality for positive dipstick proteinuria (≥+ vs. none/
trace).
doi:10.1371/journal.pone.0153429.g004
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proteinuria, with cancer mortality [12]. Unfortunately, this study did not report eGFR- or pro-
teinuria-specific results. Recently, a large US cohort study with>1 million participants
reported no association of low eGFR with total cancer incidence [33]. However, this study
found significant associations of low eGFR with kidney and urothelial cancer incidence. In our
study, although the association of low eGFR with urinary tract cancer did not reach signifi-
cance, its association with kidney cancer mortality (4 cases) was borderline significant (HR
3.14 [95%CI 0.94–10.50], p-value 0.062). We also observed that low eGFR was significantly
associated with high risk of oropharyngeal and low risk of lung cancer mortality. A strong U-
shaped relationship between eGFR and lung cancer incidence has been shown, with the lowest
incidence at eGFR 45–59 ml/min/1.73m2 and 1.5–2 fold higher incidence in high (≥90 ml/min/
1.73m2) and low (<30 ml/min/1.73m2) eGFR ranges [33]. Lung cancer patients tend to lose
weight, total body fat, and skeletal muscle mass [34], potentially explaining this U-shape, as
serum creatinine correlates with muscle mass [35]. Thus our observation of the lower risk of
lung cancer mortality in eGFR<60 (versus ≥60 ml/min/1.73m2) might reflect eGFR distribu-
tion in our study (few with eGFR<30 ml/min/1.73m2 and much more with higher eGFR).
Nevertheless, these results for type-specific cancer in our study should be considered hypothe-
sis-generating and validated in other settings.
To our knowledge, this is the first study reporting significant associations of proteinuria
with overall and type-specific cancer mortality, although a study has reported its association
with cancer incidence [36]. The associations were evident even at the level of trace or 1+ and
were observed for myeloma and cancer of several gastroenterological organs (stomach, liver,
and pancreas), lung, and urinary tract. The significant associations with lung and urinary tract
cancer mortality are consistent with the previous study examining cancer incidence [36]. There
may be several mechanisms linking proteinuria to cancer mortality. First, proteinuria may
reflect prevalent cancer [37, 38]. This is particularly relevant to myeloma releasing Bence-Jones
proteins, light polypeptide chains of immunoglobulins, and monoclonal gammopathy of unde-
termined significance in the urine. However, the significant associations in our study were con-
sistent among those without prevalent cancer at baseline and when those who died in three
years were excluded. Second, those with proteinuria may experience rapid cancer growth or
spread. Indeed, endothelial dysfunction, a condition linked to proteinuria [39], is shown to
contribute to invasiveness of cancer cells [40]. Finally, some investigators suggest inflammation
is a mediator between proteinuria and cancer incidence since inflammation influences prolifer-
ation of cells that have lost normal growth control and promotes cancer development [36, 41].
Unlike reports fromWestern countries that up to half of CKD patients dies from CVD [42,
43], non-CVD/non-cancer mortality accounted for 40%-50% of cause of death than CVD or
cancer mortality in our participants with CKD. This, is actually consistent with another report
from East Asia [17] and may be related to the fact that the incidence and mortality rates of car-
diovascular disease (particularly coronary heart disease) [44], are much lower in East Asian
countries compared to Western countries [16, 44, 45]. Therefore, health care providers in East
Asian countries should pay attention to non-CVD/non-cancer causes of death in the CKD
care. Whether this applies to East Asians living in Western countries warrants further investi-
gation. Regarding finer causes, both kidney measures were commonly and independently asso-
ciated with overall infectious disease mortality, which is consistent with a few previous reports
[19, 21, 23]. In addition, proteinuria demonstrated significant associations with death from
two specific infectious diseases, pneumonia and viral hepatitis. It is known that individuals
with CKD have reduced activities of the immune system [46].
Taken together, our findings suggest that persons with CKD warrant multidisciplinary care
for a wide range of diseases. More specifically, in addition to CVD, special attention is needed
for infectious disease prevention and management such as vaccination programs and antibiotic
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dosing [20, 46]. Also, our data suggest that individuals with proteinuria might merit consider-
ation of cancer risk. Further investigations are needed regarding how to implement cancer
screening in the context of CKD. Nevertheless, the assessment of proteinuria is already recom-
mended in some clinical populations such as diabetes and hypertension. Simultaneously, can-
cer screening programs are developed in several countries/regions for some cancers such as
lung cancer (aged 55–80 years with some smoking history) [47] and stomach cancer (aged ≥40
years) [48]. Thus, it seems reasonable to encourage persons with proteinuria to strictly adhere
to those cancer screening programs.
This study has several limitations. First, our study participants were in routine health assess-
ments at private health promotion centers and thus may not necessarily represent the general
population in Korea, particularly regarding socioeconomic status and age distribution [24].
Second, our findings may not be generalizable to those with advanced CKD (e.g., on dialysis)
since few participants had severely reduced eGFR. Third, cystatin C was not available. Cystatin
C-based eGFR is a stronger predictor of mortality and CVD outcomes than creatinine-based
eGFR [49, 50]. Thus, investigations with cystatin C for cancer and non-CVD/non-cancer mor-
tality are warranted. Fourth, we used a semi-quantitative urinary dipstick test as a measure of
kidney damage. As it does not account for urine concentration, it is likely that there were some
misclassifications of proteinuria. However, this kind of misclassification usually biases the asso-
ciation toward null. Finally, the outcome definition was based on ICD-10 codes from death cer-
tificates (S8 Table). There have been debates about the accuracy of this approach[51], and the
approach of coding primary cause may not be uniform across physicians particularly when sev-
eral comorbidities are present, e.g., diabetes and its complications. Nonetheless, it is widely
used in literature [52–54] and the accuracy of cancer death codes is high [55, 56].
In conclusion, low eGFR was mainly associated with mortality due to CVD and non-CVD/
non-cancer causes, whereas proteinuria was consistently associated mortality due to CVD, can-
cer, and other causes. Our study provides further evidence that persons with CKD (particularly
those with proteinuria) are at high risk for not only CVD but also other causes of deaths such
as cancer and infectious disease, suggesting that they may benefit from multidisciplinary pre-
vention and management strategies.
Supporting Information
S1 Fig. Adjusted hazard ratios of cause-specific mortality for eGFR<60 ml/min/1.73m2 (vs.
≥60), excluding those who died in 3 years.
(PDF)
S2 Fig. Adjusted hazard ratios of cause-specific mortality for positive dipstick proteinuria
(≥+ vs. none/trace), excluding those who died in 3 years.
(PDF)
S1 Table. ICD-10 codes of cause-specific mortality.
(DOCX)
S2 Table. Hazard ratios (95%CI) for cause-specific mortality by eGFR and age.
(DOCX)
S3 Table. Hazard ratios (95%CI) for cause-specific mortality by eGFR and gender.
(DOCX)
S4 Table. Hazard ratios (95%CI) for cause-specific mortality by eGFR and prevalent CVD
or cancer in Korean Heart Study.
(DOCX)
Kidney Disease Measures and Cause-Specific Mortality
PLOS ONE | DOI:10.1371/journal.pone.0153429 April 19, 2016 11 / 15
S5 Table. Hazard ratios (95%CI) for cause-specific mortality by dipstick proteinuria in
Korean Heart Study (excluding hospital #7), N = 178,603.
(DOCX)
S6 Table. Hazard ratios (95%CI) for cause-specific mortality by dipstick and age.
(DOCX)
S7 Table. Hazard ratios (95%CI) for cause-specific mortality by dipstick and gender.
(DOCX)
S8 Table. Hazard ratios (95%CI) for cause-specific mortality by dipstick proteinuria in
Korean Heart Study.
(DOCX)
Acknowledgments
Korean Heart Study (mortality study) participating institutes and principal
collaborators
Hyon-Suk Kim (Shinchon Severance hospital), Duk Chul Lee (Gangnam Severance hospital),
Moon Jong Kim (CHA Bundang medical center), Gyu Jang Lee (Korea medical institute),
Jidong Sung (Samsung medical center), BeLong Cho (Seoul National University), Eung Soo
Kim (Daejeon Sun general hospital), Byng-Yeon Yu (Konyang University Hospital), Tae-Yong
Lee (Chungnam National University), Jong Sung Kim (Chungnam National University), Sung
Hi Kim (Daegu Catholic University hospital), Jong-Ku Park (Yonsei University Wonju College
of Medicine), Sang Baek Koh (Yonsei University Wonju College of Medicine), Sat Byul Park
(Ajou University School of Medicine), Soon Young Lee (Ajou University School of Medicine),
Cheol-In Yoo (University of Ulsan College of Medicine), Moon Chan Kim (University of
Ulsan College of Medicine), Joo-sung Park (Dong-A University medical center)
Funding
This study was funded by a grant of the Korean Health Technology R&D Project, Ministry of
Health &Welfare, Republic of Korea (HI13C0715)
Author Contributions
Conceived and designed the experiments: YM KM SHJ JC. Performed the experiments: YM
KM. Analyzed the data: YM KM YS. Contributed reagents/materials/analysis tools: SHJ. Wrote
the paper: YM KM. Analysis and interpretation of data: YM KM YS SB MG SYS SHJ JC. Criti-
cal evaluation of the manuscript for important intellectual content: YM KM YS SB MG SYS
SHJ JC. Study supervision: KM SHJ JC.
References
1. Health NIo. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal
Disease in the United States, Bethesda, MD, 2013. http://www.usrds.org/atlas.aspx: U.S. Renal Data
System; 2013 [cited 2014 June 27]. Available from: http://www.usrds.org/atlas.aspx.
2. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimen-
sion and perspectives. Lancet. 2013; 382(9888):260–72. doi: 10.1016/S0140-6736(13)60687-X PMID:
23727169.
3. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney dis-
ease in the United States. JAMA: the journal of the American Medical Association. 2007; 298
(17):2038–47. doi: 10.1001/jama.298.17.2038 PMID: 17986697.
Kidney Disease Measures and Cause-Specific Mortality
PLOS ONE | DOI:10.1371/journal.pone.0153429 April 19, 2016 12 / 15
4. Zhang L, Wang F, Wang L, WangW, Liu B, Liu J, et al. Prevalence of chronic kidney disease in China:
a cross-sectional survey. Lancet. 2012; 379(9818):815–22. doi: 10.1016/S0140-6736(12)60033-6
PMID: 22386035.
5. Arora P, Vasa P, Brenner D, Iglar K, McFarlane P, Morrison H, et al. Prevalence estimates of chronic
kidney disease in Canada: results of a nationally representative survey. CMAJ: Canadian Medical
Association journal = journal de l'Association medicale canadienne. 2013; 185(9):E417–23. doi: 10.
1503/cmaj.120833 PMID: 23649413; PubMed Central PMCID: PMC3680588.
6. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease
in the Japanese general population. Clinical and experimental nephrology. 2009; 13(6):621–30. doi:
10.1007/s10157-009-0199-x PMID: 19513802.
7. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to
chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008;
371(9631):2173–82. doi: 10.1016/S0140-6736(08)60952-6 PMID: 18586172.
8. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality
risk: a systematic review. Journal of the American Society of Nephrology: JASN. 2006; 17(7):2034–47.
doi: 10.1681/ASN.2005101085 PMID: 16738019.
9. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as
a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based
studies. Journal of the American Society of Nephrology: JASN. 2004; 15(5):1307–15. PMID:
15100371.
10. Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey
AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardio-
vascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375
(9731):2073–81. doi: 10.1016/S0140-6736(10)60674-5 PMID: 20483451; PubMed Central PMCID:
PMC3993088.
11. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kid-
ney function, proteinuria, and adverse outcomes. JAMA: the journal of the American Medical Associa-
tion. 2010; 303(5):423–9. doi: 10.1001/jama.2010.39 PMID: 20124537.
12. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney dis-
ease and risk of major cardiovascular disease and non-vascular mortality: prospective population
based cohort study. Bmj. 2010; 341:c4986. doi: 10.1136/bmj.c4986 PMID: 20884698; PubMed Central
PMCID: PMC2948649.
13. Nagata M, Ninomiya T, Kiyohara Y, Murakami Y, Irie F, Sairenchi T, et al. Prediction of cardiovascular
disease mortality by proteinuria and reduced kidney function: pooled analysis of 39,000 individuals
from 7 cohort studies in Japan. American journal of epidemiology. 2013; 178(1):1–11. doi: 10.1093/aje/
kws447 PMID: 23752917.
14. Hallan S, Astor B, Romundstad S, Aasarod K, Kvenild K, Coresh J. Association of kidney function and
albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. Archives
of internal medicine. 2007; 167(22):2490–6. doi: 10.1001/archinte.167.22.2490 PMID: 18071172.
15. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glo-
merular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality.
A collaborative meta-analysis of high-risk population cohorts. Kidney international. 2011; 79(12):1341–
52. doi: 10.1038/ki.2010.536 PMID: 21307840.
16. World Health Organization.Causes of death: Mortality and health status. WHO data and statistics http://
apps.who.int/gho/data/node.main.CODNUMBER?lang=en: WHO Statistical Information System; [cited
2014 July 28]. Available from: http://apps.who.int/gho/data/node.main.CODNUMBER?lang=en.
17. Weng PH, Hung KY, Huang HL, Chen JH, Sung PK, Huang KC. Cancer-specific mortality in chronic
kidney disease: longitudinal follow-up of a large cohort. Clinical journal of the American Society of
Nephrology: CJASN. 2011; 6(5):1121–8. doi: 10.2215/CJN.09011010 PMID: 21511834; PubMed Cen-
tral PMCID: PMC3087779.
18. Iff S, Craig JC, Turner R, Chapman JR, Wang JJ, Mitchell P, et al. Reduced estimated GFR and cancer
mortality. American journal of kidney diseases: the official journal of the National Kidney Foundation.
2014; 63(1):23–30. doi: 10.1053/j.ajkd.2013.07.008 PMID: 23993153.
19. Fried LF, Katz R, Sarnak MJ, Shlipak MG, Chaves PH, Jenny NS, et al. Kidney function as a predictor
of noncardiovascular mortality. Journal of the American Society of Nephrology: JASN. 2005; 16
(12):3728–35. doi: 10.1681/ASN.2005040384 PMID: 16251239.
20. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work
Group M. KDIGO clinical practice guideline for evaluation and management of chronic kidney dis-
ease2013. 1–163 p.
Kidney Disease Measures and Cause-Specific Mortality
PLOS ONE | DOI:10.1371/journal.pone.0153429 April 19, 2016 13 / 15
21. Wang HE, Gamboa C, Warnock DG, Muntner P. Chronic kidney disease and risk of death from infec-
tion. American journal of nephrology. 2011; 34(4):330–6. doi: 10.1159/000330673 PMID: 21860228;
PubMed Central PMCID: PMC3169360.
22. Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV Jr. Cause-Specific Deaths in Non-Dialysis-
Dependent CKD. Journal of the American Society of Nephrology: JASN. 2015. doi: 10.1681/ASN.
2014101034 PMID: 26045089.
23. Thompson S, JamesM, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, et al. Cause of Death in
Patients with Reduced Kidney Function. Journal of the American Society of Nephrology: JASN. 2015.
doi: 10.1681/ASN.2014070714 PMID: 25733525.
24. Jee SH, Batty GD, Jang Y, Oh DJ, Oh BH, Lee SH, et al. The Korean Heart Study: rationale, objectives,
protocol, and preliminary results for a new prospective cohort study of 430,920 men and women. Euro-
pean journal of preventive cardiology. 2013; 21(12):1484–92. doi: 10.1177/2047487313497602 PMID:
23864362.
25. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to esti-
mate glomerular filtration rate. Annals of internal medicine. 2009; 150(9):604–12. PMID: 19414839;
PubMed Central PMCID: PMC2763564.
26. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the Modification of
Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum
creatinine values. Clinical chemistry. 2007; 53(4):766–72. doi: 10.1373/clinchem.2006.077180 PMID:
17332152.
27. National Bureau of Statistics. Results of the 2010 population and housing census. Seoul, Republic of
Korea: National Bureau of Statistics; 2010.
28. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classifica-
tion, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney inter-
national. 2011; 80(1):17–28. doi: 10.1038/ki.2010.483 PMID: 21150873.
29. Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, et al. Age and association of kidney
measures with mortality and end-stage renal disease. JAMA: the journal of the American Medical Asso-
ciation. 2012; 308(22):2349–60. doi: 10.1001/jama.2012.16817 PMID: 23111824; PubMed Central
PMCID: PMC3936348.
30. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in
survival analysis. Statistics in medicine. 1999; 18(6):681–94. PMID: 10204197.
31. Aguilar MI, O'Meara ES, Seliger S, LongstrethWT Jr., Hart RG, Pergola PE, et al. Albuminuria and the
risk of incident stroke and stroke types in older adults. Neurology. 2010; 75(15):1343–50. doi: 10.1212/
WNL.0b013e3181f73638 PMID: 20810996; PubMed Central PMCID: PMC3013484.
32. Mahmoodi BK, Yatsuya H, Matsushita K, Sang Y, Gottesman RF, Astor BC, et al. Association of kidney
disease measures with ischemic versus hemorrhagic strokes: pooled analyses of 4 prospective com-
munity-based cohorts. Stroke; a journal of cerebral circulation. 2014; 45(7):1925–31. doi: 10.1161/
STROKEAHA.114.004900 PMID: 24876078.
33. LowranceWT, Ordonez J, Udaltsova N, Russo P, Go AS. CKD and the Risk of Incident Cancer. Journal
of the American Society of Nephrology: JASN. 2014. doi: 10.1681/ASN.2013060604 PMID: 24876115.
34. Tisdale MJ. Cachexia in cancer patients. Nature reviews Cancer. 2002; 2(11):862–71. doi: 10.1038/
nrc927 PMID: 12415256.
35. Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, et al. Recommendations for
improving serum creatinine measurement: a report from the LaboratoryWorking Group of the National
Kidney Disease Education Program. Clinical chemistry. 2006; 52(1):5–18. doi: 10.1373/clinchem.2005.
0525144 PMID: 16332993.
36. Jorgensen L, Heuch I, Jenssen T, Jacobsen BK. Association of albuminuria and cancer incidence.
Journal of the American Society of Nephrology: JASN. 2008; 19(5):992–8. doi: 10.1681/ASN.
2007060712 PMID: 18256361; PubMed Central PMCID: PMC2386729.
37. Pedersen LM, Milman N. Microalbuminuria in patients with lung cancer. European journal of cancer.
1998; 34(1):76–80. PMID: 9624241.
38. Sawyer N, Wadsworth J, Wijnen M, Gabriel R. Prevalence, concentration, and prognostic importance
of proteinuria in patients with malignancies. Br Med J (Clin Res Ed). 1988; 296(6632):1295–8. PMID:
3133055; PubMed Central PMCID: PMC2545767.
39. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin
excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive,
interrelated, and independently associated with risk of death. Diabetes. 2002; 51(4):1157–65. PMID:
11916939.
Kidney Disease Measures and Cause-Specific Mortality
PLOS ONE | DOI:10.1371/journal.pone.0153429 April 19, 2016 14 / 15
40. Franses JW, Drosu NC, GibsonWJ, Chitalia VC, Edelman ER. Dysfunctional endothelial cells directly
stimulate cancer inflammation and metastasis. International journal of cancer Journal international du
cancer. 2013; 133(6):1334–44. doi: 10.1002/ijc.28146 PMID: 23463345; PubMed Central PMCID:
PMC3707950.
41. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420(6917):860–7. doi: 10.1038/
nature01322 PMID: 12490959; PubMed Central PMCID: PMC2803035.
42. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic
kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013; 382
(9889):339–52. doi: 10.1016/S0140-6736(13)60595-4 PMID: 23727170.
43. Stevens PE, O'Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, et al. Chronic kid-
ney disease management in the United Kingdom: NEOERICA project results. Kidney international.
2007; 72(1):92–9. doi: 10.1038/sj.ki.5002273 PMID: 17440495.
44. National Bureau of Statistics. Annual report on the cause of death statistics: National Bureau of Statis-
tics; 2012.
45. Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, et al. Cardiovascular disease and
risk factors in Asia: a selected review. Circulation. 2008; 118(25):2702–9. doi: 10.1161/
CIRCULATIONAHA.108.790048 PMID: 19106393; PubMed Central PMCID: PMCPMC3096564.
46. Janus N, Vacher LV, Karie S, Ledneva E, Deray G. Vaccination and chronic kidney disease. Nephrol-
ogy, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—
European Renal Association. 2008; 23(3):800–7. doi: 10.1093/ndt/gfm851 PMID: 18065804.
47. Davis AM, Cifu AS. Lung cancer screening. JAMA: the journal of the American Medical Association.
2014; 312(12):1248–9. doi: 10.1001/jama.2014.12272 PMID: 25247521.
48. LeungWK,Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, et al. Screening for gastric cancer in Asia:
current evidence and practice. The lancet oncology. 2008; 9(3):279–87. doi: 10.1016/S1470-2045(08)
70072-X PMID: 18308253.
49. Herget-Rosenthal S, Trabold S, Pietruck F, Holtmann M, Philipp T, Kribben A. Cystatin C: efficacy as
screening test for reduced glomerular filtration rate. American journal of nephrology. 2000; 20(2):97–
102. 13564. PMID: 10773608.
50. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of
death and cardiovascular events among elderly persons. The New England journal of medicine. 2005;
352(20):2049–60. doi: 10.1056/NEJMoa043161 PMID: 15901858.
51. Chun JH, Lee KS. Actual Conditions and Pitfalls of Death Statistics Based on the Current Death Regis-
tration System in Korea. Korean J Epidemiol. 2000; 22(2):124–35.
52. Harteloh P, de Bruin K, Kardaun J. The reliability of cause-of-death coding in The Netherlands. Euro-
pean journal of epidemiology. 2010; 25(8):531–8. doi: 10.1007/s10654-010-9445-5 PMID: 20309611.
53. Winkler V, Ott JJ, Becher H. Reliability of coding causes of death with ICD-10 in Germany. International
journal of public health. 2010; 55(1):43–8. doi: 10.1007/s00038-009-0053-7 PMID: 19636512.
54. Lu TH, Lee MC, Chou MC. Accuracy of cause-of-death coding in Taiwan: types of miscoding and
effects on mortality statistics. International journal of epidemiology. 2000; 29(2):336–43. PMID:
10817134.
55. Song YM, Sung J. Body mass index and mortality: a twelve-year prospective study in Korea. Epidemiol-
ogy. 2001; 12(2):173–9. PMID: 11246577.
56. Lee DH, Shin HR, Ahn DH, Chun BY, Kam S, Ahn YO. Accuracy of cancer death certificates in Korea.
A comparison between diagnoses in the central cancer registry and certified underlying causes of
death. J Korean Cancer Assoc. 2000; 32(1):210–9.
Kidney Disease Measures and Cause-Specific Mortality
PLOS ONE | DOI:10.1371/journal.pone.0153429 April 19, 2016 15 / 15
